Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Portal Hypertension Management Market Snapshot (2023 to 2033)

The global portal hypertension management market is expected to reach a valuation of US$ 3.05 billion in 2023, and is projected to exhibit a CAGR of 5% from 2023 to 2033. By the end of the aforementioned forecast period, the market for portal hypertension management is poised to reach US$ 4.97 billion.

Generic drugs presently dominate the market, with the scope of diagnosis including vasopressin and its analogs, beta-blockers, and somatostatin and its analogs. This also shows promising prospects for treatment advancement and research. Moreover, As the most widely used imaging method for identifying portal hypertension, duplex Doppler ultrasonography has witnessed a substantial rise in demand. As a result, this attribute is also expected to spur market growth.

The most frequent cause of portal hypertension is cirrhosis. Cirrhosis is a liver condition that develops when scar tissue substitutes healthy liver cells. As a result, the number of individuals with this condition is expected to fuel market growth. Cirrhosis is more prevalent in men than in women, based on the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. As a result, the number of aged inhabitants is anticipated to contribute to a growing market.

Because of high technological advances in health care services and boosting prevalence and occurrence of beta-blocker demand, North America holds the largest market portion. Due to its rising elderly population and elevated prognosis rate, Asia-Pacific has the second-largest market revenue. As a result of consistent increases in the incidence and occurrence of rare diseases, as well as the enhancement of in-patient groups, North America is projected to account for the majority of the market in the years ahead.

The expansion of the liver transplantation segment can be credited to the global rise in demand for transplantable organs. Based on the U.S. Department of Health and Human Services, there were approximately 122,913 diagnoses in the United States hoping for organ transplants in 2019. As a result, sophisticated transplantation items for the intervention of organ damage are in great supply. As a result, the demand for the Liver Transplantation segment is growing. Also, Huge R&D investments, as well as the greater incidence and presence of cardiovascular problems, have expanded the market for beta blocker drugs, which is anticipated to propel this segment's growth during the forecast period. As a result, the Beta Blockers segment is expected to expand significantly.

Constructively approaching reimbursement can have a beneficial impact both during the late phases of the product's creation and long after the product has been launched. Organizations and academics are collaborating to identify obstacles and opportunities that may impact Portal Hypertension R&D. The therapies in development are centered on novel strategies to treat/improve disease symptoms. Companies involved are involved in the development of Portal Hypertension therapies. The introduction of new therapies will have a massive effect on the portal hypertension management market. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Report Attribute Details
Expected Market Value (2023) US$ 3.05 Billion
Anticipated Forecast Value (2033) US$ 4.97 Billion
Projected Growth Rate (2023 to 2033) 5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Portal Hypertension Management Demand Analysis vs. Forecast 2023 to 2033

The pandemic of COVID-19 has had a modest impact on medical systems and the industry. Furthermore, the disease outbreak was disrupting the healthcare supply chain, and several companies relocated to other geographic locations throughout that time to guarantee product availability and safeguard their supply chain. As a result, the market experienced a decline during the historical period.

However, now, that the industries are getting back to their normal functioning, the global demand for Portal Hypertension Management is projected to increase at a CAGR of 5% during the forecast period between 2023 and 2033, reaching a total of US$ 4.97 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.

Which are Some Prominent Drivers of the Portal Hypertension Management Market?

The increased incidence of portal hypertension in the elderly population is predicted to drive market expansion

Accordance to the American College of Cardiology, amidst getting the highest incidence of hypertension and the elevated risk of CV death and morbidity older adults are usually underdiagnosed for high blood pressure. Based on the National Health and Nutrition Examination Survey (NHANES), hypertension impacts 70% of people over the age of 65 in the United States.

This statistic will keep rising as the population ages. According to a Pew Research Center report, the older population in the United States will thrive to 81 million by 2050, up from 37 million in 2005. Besides this, significant R&D investments, in addition to the increasing proportion and occurrence of cardiovascular problems, have enhanced the demand for portal hypertension drugs.

The increasing incidences of liver cirrhosis propel portal hypertension management market

Based on the National Center for Biotechnology Information (NCBI), liver disease causes nearly 2 million deaths worldwide each year, with 1 million due to cirrhosis comorbidities and 1 million caused by viral hepatitis and hepatocellular carcinoma.

Cirrhosis is presently the 11th major cause of death, and liver cancer is the 16th major cause of death; together, these two diseases account for 3.5% of all global mortality. As a result, the rising prevalence of liver cirrhosis is expected to drive the portal hypertension management market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Drugs side effects to Hinder Market Growth

Along with their necessary effects, the drugs may have some unintended consequences. Beta-blockers reduce heart rate. This can result in signs of low blood pressure.

Certain side effects of beta-blockers involve stomach aches, dizziness, diarrhea, or constipation, and also some people experience sexual dysfunction when obtaining them. These are a few of the considerations that the market is likely to face during the projected timeline.

Region-Wise Insights

What Makes North America the Largest Market for Portal Hypertension Management?

Increased prevalence of cardiovascular diseases and liver cirrhosis drive regional market expansion

North America will have the greatest share of the revenue in 2023. The increased incidences of cardiovascular disorders, massive R&D capital, an aging population, well-established infrastructure, and rising demands for beta-blocker drugs are some of the aspects that the market is predicted to benefit from during the forecast timeframe.

Because of the rapid growth of beta blockers in North America, the region is predicted to have the largest market share during the projected period. Furthermore, the pervasiveness of cirrhosis in the United States was estimated to be 0.27% or 633,323 adults. Sixty-nine percent said they were oblivious they had liver disease. As a result, the prevalence of liver cirrhosis in the market is expected to drive market growth.

Why is Asia Pacific Considered a Lucrative Region for the Portal Hypertension Management Market?

Because of the substantial population and expanding number of endoscopy disorder patients in Asia Pacific, the industry for portal hypertension management is anticipated to accelerate at the fastest rate over the projected period.

Furthermore, rising requirements for minimally invasive endoscopic processes and improved healthcare facilities are expected to accelerate the region's market growth. Furthermore, increased federal initiatives to modernize healthcare facilities and the continuous development of a start-up scenery are among the key factors publicizing the region's future growth.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By End User, which Segment is Projected to Lead the Market?

Hospital Segment is Estimated to Hold the Largest Share

Based on end user, the global Portal Hypertension Management market is segmented into hospital, cardiac center, ambulatory center, and other.

The hospital segment held the largest share of the market in 2022. Moreover, the same segment is expected to register the highest CAGR from 2023 to 2033.

By Treatment, Which Segment is Projected to Lead the Market?

Liver Transplantation Segment is Estimated to Account for the Largest Share

The liver transplantation segment will experience extreme growth in the upcoming years as a consequence of the increasing prevalence of passive lifestyle choices, poor eating habits, alcoholism, and drug addiction, which are among the major aspects cruising the industry's expansion.

The aging population in addition to various charities for liver problems in the world's population, has created a market for liver transplants in different regions. These elements are predicted to propel the liver transplantation market.

Market Competition

Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some latest developments by manufacturers are below

  • ONO obtained approval in Japan for Onoact® for Intravenous Infusion 50mg/150mg ("Onoact"), a short-acting selective 1 blocker, in August 2022.
  • Gilead Sciences announced in March 2021 that it would expand its collaboration with Novo Nordisk and develop knowledge of the potential for composite strategies in treating individuals with cirrhosis caused by NASH which will further contribute to the portal hypertension management market.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 3.05 billion
Market Value in 2033 US$ 4.97 billion
Growth Rate CAGR of 5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Treatment
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Ono Pharmaceutical Co., Ltd.
  • United Therapeutics Corporation
  • Chiasma Inc.
  • Genextra S.p.a.
  • Gilead Sciences Inc.
  • Debiovision, Inc.
  • Govind Ballabh Pant Hospital
  • Dr. Falk Pharma GmbH
  • Novartis AG
  • Sun Pharmaceuticals Industries Ltd.
Customization Available Upon Request

Key Segments Profiled in the Portal Hypertension Management Industry Survey

By Treatment:

  • Liver Transplantation
  • Endoscopic Therapy
    • Banding
    • Balloon Tamponade
  • Shunting Procedures
    • Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
    • Surgical Shun
  • Drug Class
    • Octapeptides
    • Cofactors
    • PDE5 Inhibitor
    • Beta Blockers

By End Users:

  • Hospitals
  • Specialty Clinic
  • Others

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

What is the Projected CAGR of the Portal Hypertension Management Market by 2033?

The projected CAGR of the portal hypertension management market by 2033 is 5%.

What is the Projected Portal Hypertension Management Market value by 2033?

The projected market value by 2033 is US$ 4.97 billion.

What is the Current Portal Hypertension Management Market Valuation?

The market is estimated to secure a valuation of US$ 3.05 billion in 2023.

Which Industry is the Key Consumer of the Portal Hypertension Management Market?

The healthcare industry is the key consumer.

Who are the Three Key Players in the Portal Hypertension Management Market?

Gilead Sciences, Daiichi Sankyo, and Ono Pharmaceutical Co., Ltd. are the key players in the market.

Table of Content

1. Executive Summary | Portal Hypertension Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Liver Transplantation

        5.3.2. Endoscopic Therapy

            5.3.2.1. Banding

            5.3.2.2. Balloon Tamponade

        5.3.3. Shunting Procedures

            5.3.3.1. Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt

            5.3.3.2. Surgical Shunts

        5.3.4. Drug Class

            5.3.4.1. Octapeptides

            5.3.4.2. Cofactors

            5.3.4.3. PDE5 Inhibitors

            5.3.4.4. Beta Blockers

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Specialty Clinics

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. United States

            8.2.1.2. Canada

        8.2.2. By Treatment

        8.2.3. By End Users

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Treatment

        8.3.3. By End Users

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Treatment

        9.2.3. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By End Users

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Treatment

        10.2.3. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By End Users

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Treatment

        11.2.3. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By End Users

    11.4. Key Takeaways

12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By

    12.1. Country

    12.2. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.3. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. GCC Countries

            12.3.1.2. South Africa

            12.3.1.3. Israel

            12.3.1.4. Rest of MEA

        12.3.2. By Treatment

        12.3.3. By End Users

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Treatment

        12.4.3. By End Users

    12.5. Key Takeaways

13. Key Countries Market Analysis

    13.1. United States

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Treatment

            13.1.2.2. By End Users

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Treatment

            13.2.2.2. By End Users

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Treatment

            13.3.2.2. By End Users

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Treatment

            13.4.2.2. By End Users

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Treatment

            13.5.2.2. By End Users

    13.6. United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Treatment

            13.6.2.2. By End Users

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Treatment

            13.7.2.2. By End Users

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Treatment

            13.8.2.2. By End Users

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Treatment

            13.9.2.2. By End Users

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Treatment

            13.10.2.2. By End Users

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Treatment

            13.11.2.2. By End Users

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Treatment

            13.12.2.2. By End Users

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Treatment

            13.13.2.2. By End Users

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Treatment

            13.14.2.2. By End Users

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Treatment

            13.15.2.2. By End Users

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Treatment

            13.16.2.2. By End Users

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Treatment

            13.17.2.2. By End Users

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Treatment

            13.18.2.2. By End Users

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Treatment

            13.19.2.2. By End Users

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Treatment

            13.20.2.2. By End Users

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Treatment

        14.3.3. By End Users

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Ono Pharmaceutical Co., Ltd.

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. United Therapeutics Corporation

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Chiasma, Inc.

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Genextra S.p.a.

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Gilead Sciences, Inc.

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Debiovision, Inc.

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Govind Ballabh Pant Hospital

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Dr. Falk Pharma GmbH

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Novartis AG.

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Sun Pharmaceuticals Industries Ltd.

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Recommendations

Healthcare

Pulmonary Arterial Hypertension Treatment Market

Published : September 2023

Healthcare

Heart Closure Devices Market

Published : December 2022

Explore Healthcare Insights

View Reports

Portal Hypertension Management Market